MedTrace Logo

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCT06196840 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-03-06

No results posted yet for this study

Summary

The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

GENETIC

LX102 subretinal injection

LX102: AAV-based gene therapy comprised of codon-optimized sequence encoding VEGF-trap

BIOLOGICAL

Aflibercept intravitreal injection

Commercially available Active Comparator

Sponsors & Collaborators

  • Innostellar Biotherapeutics Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2025-06-24
Completion
2029-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06196840 on ClinicalTrials.gov